OLD Category: Oncology

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers

• Wolf G.T. et. al.,

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

• Calcinotto A. et. al.,

More than Fishing for a Cure: The Promises and Pitfalls of High Throughput Cancer Cell Line Screens

• Ling A et al.,

TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases

• Williams L.A. et. al.,

MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma

• Pettit C. et. al.,

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

• Danaher P. et. al.,

CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma

• Liang L. et. al.,

Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies

• Xu P-P. et. al.,

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche

• Tsukamoto S. et. al.,

Patient derived organoids to model rare prostate cancer phenotypes

• Puca L. et. al., 2018

Molecular Characterization and Putative Pathogenic Pathways of Tuberous Sclerosis Complex–Associated Renal Cell Carcinoma

• Park J.H. et. al.,

Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes

• Sundar R. et. al.,